Table 3.
Change in Outcome Measures after 8 weeks (Intention-to-treat analysis) (n = 55-60)
| Variable | Blend 1 (mean ± SD) |
Blend 2 (mean ± SD) |
Placebo (mean ± SD) |
|---|---|---|---|
| Endothelial Function | |||
| Flow-mediated dilatation, % | 0.70 ± 3.70 | 0.70 ± 3.80 | 0.60 ± 3.70 |
| Stimulus-adjusted response measure | -0.02 ± 0.23 | -0.02 ± 0.21 | -0.03 ± 0.21 |
| Flow-mediated dilatation, % (acute effects) | 1.1 ± 3.70 | 0.7 ± 3.5 | -0.3 ± 5.4 |
| Serum Measures | |||
| Insulin, pmol/L | 68.06 ± 311.83 | 18.06 ± 213.21 | 15.97 ± 202.79 |
| Fasting plasma glucose, mmol/L | 0.03 ± 1.44 | 0.16 ± 1.47 | 0.38 ± 1.58 |
| Anthropometric Measures | |||
| Body Weight, kg | 0.40 ± 2.20 | 0.30 ± 2.80 | 0.40 ± 2.20 |
| Body Mass Index, kg/m2 | 0.10 ± 0.80 | 0.10 ± 1.00 | 0.10 ± 0.80 |
| Lipid Panel | |||
| Total Cholesterol, mmol/L | 0.08 ± 0.47 | 0.08 ± 0.60 | 0.03 ± 0.52 |
| High Density Lipoprotein (HDL), mmol/L | 0.04 ± 0.17 | 0.04 ± 0.12 | 0.06 ± 0.15 |
| Total Cholesterol/HDL | -0.10 ± 0.60 | -0.10 ± 0.80 | -0.30 ± 0.70 |
| Triglycerides, mmol/L | 0.02 ± 0.64 | -0.01 ± 0.71 | -0.13 ± 0.68 |
| Low Density Lipoprotein (LDL), mmol/L | -0.02 ± 0.53 | 0.08 ± 0.62 | 0.02 ± 0.53 |
p > 0.05 for all pairwise comparisons